GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zhaoke Ophthalmology Ltd (HKSE:06622) » Definitions » Other Operating Expense

Zhaoke Ophthalmology (HKSE:06622) Other Operating Expense : HK$89.75 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Zhaoke Ophthalmology Other Operating Expense?

Zhaoke Ophthalmology's Other Operating Expense for the six months ended in Dec. 2024 was HK$89.75 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 was HK$89.75 Mil.

Zhaoke Ophthalmology's quarterly Other Operating Expense declined from Dec. 2023 (HK$98.16 Mil) to Jun. 2024 (HK$0.00 Mil) but then increased from Jun. 2024 (HK$0.00 Mil) to Dec. 2024 (HK$89.75 Mil).

Zhaoke Ophthalmology's annual Other Operating Expense increased from Dec. 2022 (HK$95.22 Mil) to Dec. 2023 (HK$98.16 Mil) but then declined from Dec. 2023 (HK$98.16 Mil) to Dec. 2024 (HK$89.75 Mil).

Zhaoke Ophthalmology Other Operating Expense Historical Data

The historical data trend for Zhaoke Ophthalmology's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhaoke Ophthalmology Other Operating Expense Chart

Zhaoke Ophthalmology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Operating Expense
Get a 7-Day Free Trial 23.36 135.77 95.22 98.16 89.75

Zhaoke Ophthalmology Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 95.22 - 98.16 - 89.75

Zhaoke Ophthalmology Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$89.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhaoke Ophthalmology Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Zhaoke Ophthalmology's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhaoke Ophthalmology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zhaoke Ophthalmology Ltd (HKSE:06622) » Definitions » Other Operating Expense
Comparable Companies
HKSE:02137 HKSE:02511 HKSE:01875 HKSE:06998 HKSE:03681 HKSE:02566 HKSE:01244 HKSE:02563 HKSE:02898 HKSE:02496 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
9FX:Germany
Address
No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangdong Province, Guangzhou, CHN
Website
https://www.zkoph.com
Zhaoke Ophthalmology Ltd is a ophthalmic pharmaceutical company dedicated to the research, development, manufacture and commercialization of therapies that address significant unmet medical needs. The company has three flagship drug assets processing towards potential market approval NVK002 for myopia, CsA Ophthalmic Gel for DED and TAB014 for wAMD; and two promising drug assets in the clinical stage BRIMOCHOL PF for presbyopia and ZKY001 for corneal epithelial defects. Geographically the company operates in Hong Kong, Mainland China, South Korea, and Others.
Executives
Mak Siu Hang Viola 2201 Interest of corporation controlled by you
Gic Private Limited 2201 Interest of corporation controlled by you
Apstar Investment Pte Ltd 2201 Interest of corporation controlled by you
Coyote Investment Pte Ltd 2101 Beneficial owner
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Fidelity China Special Situations Plc 2101 Beneficial owner
Fil Limited 2201 Interest of corporation controlled by you
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
Citigroup Inc. 2502 Approved lending agent
Vms Holdings Limited 2201 Interest of corporation controlled by you
Lee's Pharmaceutical Holdings Limited 2201 Interest of corporation controlled by you
Tpg Asia Genpar Vii, L.p. 2201 Interest of corporation controlled by you
Tpg Holdings Iii-a, L.p. 2201 Interest of corporation controlled by you

Zhaoke Ophthalmology Headlines

No Headlines